Decrease (-) Restore Default Increase (+)
CornerStone Vol. 25, No. 1, Summer 2015
conerstone-cover-summer2015.jpg
Front page...

NYU Winthrop's Medically Supervised Weight Management Program Helps Local Residents
NYU Winthrop Elects Two New Members to its Board of Directors
In Memoriam
College-bound Student Athlete Finds Relief from Sinusitis
New Research and Academic Center Celebrates Grand Opening
NYU Winthrop Recognized by U.S. News & World Report for Outstanding Pediatric Care
New Drugs, New Hope for Patients Facing Lung Cancer
NYU Winthrop Earns Designation as a Lung Cancer Screening Center by the ACR
New Equipment Enhances Care for Pediatric Airway Emergencies
Grateful Family Gives Back to NICU
The Kornreich Family Makes Donation in Honor of Young Patient
A Leader in Research
Sports Medicine Program Gives Back to the Community with Student Athlete Scholarships
Long Island's First and Only Baby-Friendly Hospital
Celebration of the Theresa M. Santmann Biomedical Research Laboratory Signals Final Stage of the Opening of the Research and Academic Center
A Bite of Hope for Pediatric Diabetes Patients
The Starlight Foundation Delivers Tablets to Pediatric Inpatient Center
NYU Winthrop Partners With Local Boy Scout to Provide Vital Resource to the Mineola Community
Once Again, NYU Winthrop Earns Designation As NAEC Level 4 Epilepsy Center
Ninth Annual Black & White Ball Raises More Than $300,000 for NYU Winthrop's CCFK
Spirit of Children Brings the Spirit of Philanthropy to Cancer Center for Kids
A Lap Goes a Long Way for Child Life at NYU Winthrop
Verizon Foundation Helps Give Patients and Their Families Peace of Mind
Local Kiwanis Club Shows Continued Support
The Book Fairies Make a Special Delivery
A Cause to Celebrate Raises Nearly $120,000 for NYU Winthrop's Child Life Program
An Evening in Tuscany - Gala Raises Over $950,000 for NYU Winthrop
30th Anniversary Golf Tournament Raises $650,000 for NYU Winthrop's Research Programs
Ask the Expert - Women's Health: Bladder and Pelvic Floor Disorders
Glen Oaks Country Club Shows Continued Support for NYU Winthrop
Senator Jack M. Martins Delivers Toys to Young Patients
New York Islanders Bring Cheer to Young Patients
An Early Mother's Day at NYU Winthrop
The Irish American Golf Club Makes Donation in Honor of Former Captain
Yuletide Ball Raises Over $216,000 for Child Life Program
 

New Drugs, New Hope for Patients Facing Lung Cancer

Guo Lin is just one of the lung cancer patients at NYU Winthrop who has had great success with a clinical trial led by Jeff Schneider, MD, Interim Chief of Oncology/Hematology and Director of the Lung Cancer Program, for a new immunotherapy drug, Opdivo.

When Guo Lin arrived at NYU Winthrop’s Lung Cancer Center in October 2014, his progno- sis was grim. The 51-year-old former small business owner had been diagnosed with lung cancer in 2013 and initially responded well to traditional chemotherapy. Before long, though, symptoms returned, and his physician suggested participation in a clinical trial of a new immunotherapy drug, Opdivo┬«.

Lin and his family came to NYU Winthrop, the only Long Island hospital that participated in the trial that culminated in the recent approval of the drug by the Food and Drug Administration in March 2015. Opdivo is the first drug ever approved for lung cancer that works by enabling the body’s own immune system to fight the cancer. Opdivo inhibits a protein present in advanced-stage non-small cell lung cancer cells that blocks the immune system from attacking the cancer cells.

“I was concerned about being in a trial,” Mr. Lin said, “But the doctors explained everything carefully and I was comfortable moving ahead. Everyone at NYU Winthrop has been so kind and professional.”

“We administered his first dose of Opdivo in late October and Mr. Lin experienced almost immediate relief of symptoms,” explained Jeff Schneider, MD, Interim Chief of Oncology/Hematology and Director of the Lung Cancer Program. “After six weeks of therapy with no side effects, repeat CT scans showed dramatic improvement in diffuse metastases. Most recent scans show ongoing tumor regression and no new sites of disease.” An active man who prior to his illness enjoyed jogging and playing basketball, Mr. Lin is back participating in many activities he enjoys.

“The real excitement here is that, unlike what we see with responses to conventional chemotherapy, these immunologic responses are long lasting and promise to return nor- mal longevity to patients like Mr. Lin. The goal now is to make this work for all of our cancer patients,” Dr. Schneider said.

For more information about NYU Winthrop’s Lung Cancer Program and the Opdivo trial, call 1-866-WINTHROP.